Drugs / ABBV-119
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04853368 | Sep 2021 → Jun 2023 | cystic fibrosis | AbbVie | Terminated | Mixed Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853368 ↗ |
| Route | Oral | “Oral capsules” NCT04853368 ↗ |